News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>Nomura Lifts HANSOH PHARMA's TP to HKD37.87 w/ Higher Rev. & Earnings Forecast
HANSOH PHARMA (03692.HK) expects to achieve a 10% growth in both revenue and earnings for FY26, according to Nomura's research report.In Nomura's estimate, HANSOH PHARMA...
Reset
Send
The window will close in 5 seconds
<Research>Nomura Lifts HANSOH PHARMA's TP to HKD37.87 w/ Higher Rev. & Earnings Forecast
Close
Recommend
2
Positive
1
Negative
2
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

HANSOH PHARMA (03692.HK)  +1.940 (+5.184%)    Short selling $228.42M; Ratio 121.536%   expects to achieve a 10% growth in both revenue and earnings for FY26, according to Nomura's research report.

In Nomura's estimate, HANSOH PHARMA's 2H25 revenue will have grown by 27% YoY to RMB7.3 billion, slightly above market consensus, including a 17% YoY growth in drug sales to RMB6.6 billion and recognition of RMB743 million in collaboration revenue.

Related NewsHaitong International: HANSOH PHARMA (03692.HK) Sees Steady Growth in Innovative Products, Pipeline Entering Breakout Phase
Nomura has raised its FY25 revenue and earnings forecasts for HANSOH PHARMA by 1% and 4.7% respectively to account for higher collaboration revenue. HANSOH PHARMA's target price has increased from HKD35.5 to HKD37.87, with a Neutral rating remaining in place.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-02 16:25.)

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.